{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:00:53Z","timestamp":1780131653051,"version":"3.54.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10096-025-05383-3","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:17:30Z","timestamp":1767705450000},"page":"1477-1481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Could oritavancin be a promising alternative treatment for staphylococcal bone and joint infections? Insights from the determination of oritavancin minimum inhibitory concentrations in a collection of clinical isolates from the French National reference centre for staphylococci"],"prefix":"10.1007","volume":"45","author":[{"given":"M.","family":"Berrada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kolenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tristan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dupieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"5383_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1634-6939(10)45389-2","volume":"5","author":"F Caby","year":"2010","unstructured":"Caby F, Bismuth R, Bossi P (2010) Infections \u00e0 staphylocoques. EMC - Trait\u00e9. M\u00e9decine AKOS 5:1\u20137. https:\/\/doi.org\/10.1016\/S1634-6939(10)45389-2","journal-title":"M\u00e9decine AKOS"},{"issue":"Suppl 3","key":"5383_CR2","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1093\/cid\/cir923","volume":"54","author":"RE Mendes","year":"2012","unstructured":"Mendes RE, Farrell DJ, Sader HS, Jones RN (2012) Oritavancin microbiologic features and activity results from the surveillance program in the united States. Clin Infect Dis Off Publ Infect Dis Soc Am 54(Suppl 3):S203\u2013213. https:\/\/doi.org\/10.1093\/cid\/cir923","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"5383_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40121-016-0103-4","volume":"5","author":"KD Brade","year":"2016","unstructured":"Brade KD, Rybak JM, Rybak MJ (2016) Oritavancin: a new lipoglycopeptide antibiotic in the treatment of gram-positive infections. Infect Dis Ther 5:1\u201315. https:\/\/doi.org\/10.1007\/s40121-016-0103-4","journal-title":"Infect Dis Ther"},{"key":"5383_CR4","doi-asserted-by":"publisher","first-page":"ofz479","DOI":"10.1093\/ofid\/ofz479","volume":"6","author":"M Redell","year":"2019","unstructured":"Redell M, Sierra-Hoffman M, Assi M, Bochan M, Chansolme D, Gandhi A et al (2019) The CHROME study, a real-world experience of single- and multiple-dose Oritavancin for treatment of gram-positive infections. Open Forum Infect Dis 6:ofz479. https:\/\/doi.org\/10.1093\/ofid\/ofz479","journal-title":"Open Forum Infect Dis"},{"key":"5383_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.diagmicrobio.2018.05.010","volume":"92","author":"Q Yan","year":"2018","unstructured":"Yan Q, Karau MJ, Patel R (2018) In vitro activity of Oritavancin against biofilms of Staphylococci isolated from prosthetic joint infection. Diagn Microbiol Infect Dis 92:155\u2013157. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.05.010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"5383_CR6","doi-asserted-by":"publisher","first-page":"e00943","DOI":"10.1128\/AAC.00943-18","volume":"62","author":"Q Yan","year":"2018","unstructured":"Yan Q, Karau MJ, Raval YS, Patel R (2018) Evaluation of Oritavancin combinations with rifampin, gentamicin, or linezolid against prosthetic joint infection-associated methicillin-resistant Staphylococcus aureus biofilms by time-kill assays. Antimicrob Agents Chemother 62:e00943\u2013e00918. https:\/\/doi.org\/10.1128\/AAC.00943-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5383_CR7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1128\/AAC.00766-08","volume":"53","author":"A Belley","year":"2009","unstructured":"Belley A, Neesham-Grenon E, McKay G, Arhin FF, Harris R, Beveridge T et al (2009) Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother 53:918\u2013925. https:\/\/doi.org\/10.1128\/AAC.00766-08","journal-title":"Antimicrob Agents Chemother"},{"key":"5383_CR8","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1128\/AAC.47.7.2283-2292.2003","volume":"47","author":"C Seral","year":"2003","unstructured":"Seral C, Van Bambeke F, Tulkens PM (2003) Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and Oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother 47:2283\u20132292. https:\/\/doi.org\/10.1128\/AAC.47.7.2283-2292.2003","journal-title":"Antimicrob Agents Chemother"},{"key":"5383_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1128\/AAC.50.3.841-851.2006","volume":"50","author":"M Barcia-Macay","year":"2006","unstructured":"Barcia-Macay M, Seral C, Mingeot-Leclercq M-P, Tulkens PM, Van Bambeke F (2006) Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 50:841\u2013851. https:\/\/doi.org\/10.1128\/AAC.50.3.841-851.2006","journal-title":"Antimicrob Agents Chemother"},{"key":"5383_CR10","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1128\/AAC.00981-15","volume":"59","author":"D Lehoux","year":"2015","unstructured":"Lehoux D, Ostiguy V, Cadieux C, Malouin M, Belanger O, Far AR et al (2015) Oritavancin pharmacokinetics and bone penetration in rabbits. Antimicrob Agents Chemother 59:6501\u20136505. https:\/\/doi.org\/10.1128\/AAC.00981-15","journal-title":"Antimicrob Agents Chemother"},{"key":"5383_CR11","first-page":"407","volume":"64","author":"S Swoboda","year":"2009","unstructured":"Swoboda S, Helbig L, Kommerell M, Simank HG, Kees F, Geiss HK et al (2009) Bone tissue and plasma concentrations of linezolid and Vancomycin in rabbits with prosthesis-related infection due to MRSA. Pharm 64:407\u2013409","journal-title":"Pharm"},{"key":"5383_CR12","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1128\/AAC.42.11.2830","volume":"42","author":"A Saleh Mghir","year":"1998","unstructured":"Saleh Mghir A, Cr\u00e9mieux AC, Bleton R, Ismael F, Manteau M, Dautrey S et al (1998) Efficacy of Teicoplanin and autoradiographic diffusion pattern of [14\u00a0C]teicoplanin in experimental Staphylococcus aureus infection of joint prostheses. Antimicrob Agents Chemother 42:2830\u20132835. https:\/\/doi.org\/10.1128\/AAC.42.11.2830","journal-title":"Antimicrob Agents Chemother"},{"key":"5383_CR13","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1128\/AAC.00020-07","volume":"51","author":"EG Solon","year":"2007","unstructured":"Solon EG, Dowell JA, Lee J, King SP, Damle BD (2007) Distribution of radioactivity in bone and related structures following administration of [14\u00a0C]dalbavancin to new Zealand white rabbits. Antimicrob Agents Chemother 51:3008\u20133010. https:\/\/doi.org\/10.1128\/AAC.00020-07","journal-title":"Antimicrob Agents Chemother"},{"key":"5383_CR14","unstructured":"EUCAST (2025) Clinical breakpoints and dosing of antibiotics n.d. https:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"5383_CR15","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/jac\/dkaf042","volume":"80","author":"BJ Werth","year":"2025","unstructured":"Werth BJ, Zhang R, Barreras Beltran IA, Penewit K, Waalkes A, Holmes EA et al (2025) Simulated exposures of Oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to Oritavancin but minimal cross-resistance or Seesaw effect with other antimicrobials. J Antimicrob Chemother 80:1108\u20131115. https:\/\/doi.org\/10.1093\/jac\/dkaf042","journal-title":"J Antimicrob Chemother"},{"key":"5383_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2217\/fmb-2017-0310","volume":"13","author":"G Fl\u00fch","year":"2018","unstructured":"Fl\u00fch G, Seifert H, Kaasch AJ (2018) Oritavancin: an update. Future Microbiol 13:727\u2013729. https:\/\/doi.org\/10.2217\/fmb-2017-0310","journal-title":"Future Microbiol"},{"key":"5383_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40801-020-00195-7","volume":"7","author":"NW Van Hise","year":"2020","unstructured":"Van Hise NW, Chundi V, Didwania V, Anderson M, McKinsey D, Roig I et al (2020) Treatment of acute osteomyelitis with once-weekly oritavancin: a two-year, multicenter, retrospective study. Drugs - Real World Outcomes 7:41\u201345. https:\/\/doi.org\/10.1007\/s40801-020-00195-7","journal-title":"Drugs - Real World Outcomes"},{"key":"5383_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/phar.2057","volume":"38","author":"LT Schulz","year":"2018","unstructured":"Schulz LT, Dworkin E, Dela-Pena J, Rose WE (2018) Multiple-dose Oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacotherapy 38:152\u2013159. https:\/\/doi.org\/10.1002\/phar.2057","journal-title":"Pharmacotherapy"},{"key":"5383_CR19","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/phar.1957","volume":"37","author":"DJ Delaportas","year":"2017","unstructured":"Delaportas DJ, Estrada SJ, Darmelio M (2017) Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with Oritavancin. Pharmacotherapy 37:e90\u2013e92. https:\/\/doi.org\/10.1002\/phar.1957","journal-title":"Pharmacotherapy"},{"key":"5383_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ijantimicag.2018.11.023","volume":"53","author":"DB Chastain","year":"2019","unstructured":"Chastain DB, Davis A (2019) Treatment of chronic osteomyelitis with multidose oritavancin: a case series and literature review. Int J Antimicrob Agents 53:429\u2013434. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.023","journal-title":"Int J Antimicrob Agents"},{"key":"5383_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/IPC.0000000000000599","author":"Michael A. Ruggero","year":"2018","unstructured":"Ruggero MA, Ziegler MJ, Tebas P, Binkley A, Kelly BJ (2018) Successful treatment of methicillin-resistant staphylococcus aureus vertebral osteomyelitis with outpatient oritavancin therapy. Infect Dis Clin Pract 26:141. https:\/\/doi.org\/10.1097\/IPC.0000000000000599","journal-title":"Infectious Diseases in Clinical Practice"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05383-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:04:04Z","timestamp":1780128244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05383-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5383"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05383-3","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}